Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
NCT07296341

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2026-01-14

60

Participants Needed

1

Research Sites

98 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors

CONDITIONS

Official Title

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years old, any gender
  • ECOG performance status of 0 or 1
  • Life expectancy of at least 12 weeks
  • Diagnosed with unresectable locally advanced or metastatic pancreatic cancer
  • Pancreatic duct adenocarcinoma confirmed by histopathology
  • Provide tumor tissue samples obtained within 3 years before starting treatment
  • Have at least one measurable tumor lesion according to RECIST 1.1 criteria
Not Eligible

You will not qualify if you...

  • Untreated or active central nervous system tumor metastasis
  • Not recovered from previous treatment side effects or complications to the required safety levels
  • Known or suspected interstitial pneumonia
  • Grade 3 or higher serous fluid buildup or large abdominal fluid accumulation needing recent drainage
  • Acute or chronic pancreatitis with significant clinical symptoms

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

Z

Zengquan Gu

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors | DecenTrialz